BNC lands cancer drug formulation contract

- Last updated on GMT

Bio Nano Consulting (BNC) says University of London School of Pharmacy deal helped land first Ph I trial formulation services contract.

The UK firm, a nanotechnology partnering focused JV between the University of London School of Pharmacy and Imperial College London, will mange development of an orally-available formulation of a candidate cancer treatment for an undisclosed US biotech developer.

The proof-of-concept project, which will be conducted by researchers at the School of Pharmacy, follows signing of a service level agreement (SLA) with the institution and extends the scope of BNC’s trial support expertise according to CEO David Sarphie.

The SLA significantly expands our established pool of world class scientist that we manage and draw upon for specific life science projects, including cancer research​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers